Fluid Biomarker Changes After Amyloid-β–Targeting Drugs-Reference-Cited by-同舟云学术

Fluid Biomarker Changes After Amyloid-β–Targeting Drugs

Published:2024-06-01 Issue:6 Volume:81 Page:579
ISSN:2168-6149
Container-title:JAMA Neurology
language:en
Short-container-title:JAMA Neurol

Author:

Ossenkoppele Rik¹²³,Teunissen Charlotte E.²⁴

Affiliation:

1. Neurology, Alzheimer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands

2. Neurodegeneration, Amsterdam Neuroscience, Amsterdam, the Netherlands

3. Clinical Memory Research Unit, Lund University, Lund, Sweden

4. Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands

Publisher

American Medical Association (AMA)

Link

https://jamanetwork.com/journals/jamaneurology/articlepdf/2817636/jamaneurology_ossenkoppele_2024_ed_240003_1717440923.43218.pdf

Reference15 articles.

1. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial.;Sims;JAMA,2023

2. Lecanemab in Early Alzheimer’s disease.;van Dyck;N Engl J Med,2023

3. Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease.;Budd Haeberlein;J Prev Alzheimers Dis,2022

4. Downstream biomarker effects of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease: the DIAN-TU-001 randomized clinical trial.;Wagemann;JAMA Neurology,2024

5. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease.;Salloway;Nat Med,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements in the Early Identification and Treatment of Alzheimer’s Disease;EMJ Neurology;2024-08-13